Plant Name: Entada africana
Taxonomic Information:
Plant ID: NPO11507
Plant Latin Name: Entada africana
Taxonomy Genus: Entada
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
493820-1
Used in Medicines:
Country/Region:
Guinea; Nigeria; Burkina FasoTraditional Medicine System:
Geographical Distribution:
Ghana; Mauritania; Uganda; Chad; Togo; Sudan; Gambia; Mali; Senegal; Burkina Faso; Ethiopia; Nigeria; Guinea-Bissau; Guinea; Niger; Cameroon; Cote d'Ivoire; Benin
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ACHE; | |
| CDK8; FLT3; CSNK2A1; | |
| CA7; CA4; CA12; CA9; | |
| ESR2; | |
| NOX4; HSD17B1; | |
| MMP12; | |
| HIF1A; | |
| THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.998E-12 | 6.527E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, NOX4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.398E-10 | 1.523E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 9.062E-10 | 4.933E-06 | CA12, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.902E-09 | 8.285E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, NOX4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.959E-09 | 1.231E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.850E-09 | 1.592E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.860E-08 | 7.641E-05 | CA12, CA4, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.851E-08 | 1.606E-04 | CA12, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.878E-07 | 4.222E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.411E-06 | 1.280E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 3.525E-06 | 2.254E-03 | CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FLT3, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 4.736E-06 | 2.787E-03 | CYP19A1, CYP1A1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 5.494E-06 | 3.148E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.372E-05 | 6.688E-03 | CYP1A2, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.413E-05 | 6.688E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, HSD17B1, NOX4 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.938E-09 | 3.876E-08 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.373E-09 | 3.876E-08 | CA12, CA4, CA7, CA9 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.303E-07 | 1.737E-06 | HSD17B1, CYP1A1, CYP1B1, CYP19A1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 9.706E-07 | 9.706E-06 | CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 7.024E-06 | 5.619E-05 | CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.335E-05 | 2.890E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.419E-04 | 1.954E-03 | CYP1A2, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.822E-03 | 7.725E-03 | FLT3, HIF1A |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.716E-03 | 7.725E-03 | CYP1A2, CYP1A1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.931E-03 | 7.725E-03 | CYP1A2, CYP2C19 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT3; HIF1A; CA9; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| C00-D49: Neoplasms | AML | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; CYP19A1; CA9; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; FLT3; ACHE; HIF1A; CA9; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
